Nine Pyroptosis-Related lncRNAs are Identified as Biomarkers for Predicting the Prognosis and Immunotherapy of Endometrial Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–1149. doi:10.1097/AOG.0b013e3181f39849
   PubMed Web of Science ®Google Scholar
• Degez M, Caillon H, Chauviré-Drouard A, et al. Endometrial cancer: a systematic review of HE4, REM and REM-B. Clin Chim Acta. 2021;515:27–36. doi:10.1016/j.cca.2020.12.029
   PubMed Web of Science ®Google Scholar
• Espiau Romera A, Coronado Martín PJ, Chóliz Ezquerro M, Cuesta Guardiola T, Adiego Calvo I, Baquedano Mainar L. Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer. Int J Gynaecol Obstet. 2021;153(1):64–70. doi:10.1002/ijgo.13473
   PubMed Web of Science ®Google Scholar
• Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens. Immunol Rev. 2015;265(1):130–142. doi:10.1111/imr.12287
   PubMed Web of Science ®Google Scholar
• Wang F, Li G, Ning J, et al. Alcohol accumulation promotes esophagitis via pyroptosis activation. Int J Biol Sci. 2018;14(10):1245–1255. doi:10.7150/ijbs.24347
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin B, Li D, Wang G, Han X, Sun X. GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. Biochem Biophys Res Commun. 2018;495(1):1418–1425. doi:10.1016/j.bbrc.2017.11.156
   PubMed Web of Science ®Google Scholar
• Pizato N, Luzete BC, Kiffer L, et al. Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells. Sci Rep. 2018;8(1):1952. doi:10.1038/s41598-018-20422-0
   PubMed Web of Science ®Google Scholar
• Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: the route to “Ithaca”. Diagnostics. 2019;9(2):55. doi:10.3390/diagnostics9020055
   Web of Science ®Google Scholar
• Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–914. doi:10.1016/j.molcel.2011.08.018
   PubMed Web of Science ®Google Scholar
• Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–361. doi:10.1016/j.tcb.2011.04.001
   PubMed Web of Science ®Google Scholar
• Wang X, Ren Y, Yang X, et al. miR-190a inhibits epithelial-mesenchymal transition of hepatoma cells via targeting the long non-coding RNA treRNA. FEBS Lett. 2015;589(24 Pt B):4079–4087. doi:10.1016/j.febslet.2015.11.024
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen Y, Lin C, Hu G. Biological functions and clinical significance of the newly identified long non‑coding RNA RP1‑85F18.6 in colorectal cancer. Oncol Rep. 2018;40(5):2648–2658. doi:10.3892/or.2018.6694
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Li Y, Chen A, Li L, You Z. LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Biosci Rep. 2018;38(2). doi:10.1042/bsr20171150
   Web of Science ®Google Scholar
• Chen G, Zhang M, Liang Z, et al. Association of polymorphisms in MALAT1 with the risk of endometrial cancer in Southern Chinese women. J Clin Lab Anal. 2020;34(4):e23146. doi:10.1002/jcla.23146
   PubMed Web of Science ®Google Scholar
• Gu ZR, Liu W. The lncRNA AL161431.1 targets miR-1252-5p and facilitates cellular proliferation and migration via MAPK signaling in endometrial carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(5):2294–2302. doi:10.26355/eurrev_202003_20495
   PubMed Web of Science ®Google Scholar
• Wang J, Li Z, Wang X, Ding Y, Li N. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in uteri corpus endometrial carcinoma. Life Sci. 2020;243:117254. doi:10.1016/j.lfs.2020.117254
   PubMed Web of Science ®Google Scholar
• Yang W, Yue Y, Yin F, Qi Z, Guo R, Xu Y. LINC01133 and LINC01243 are positively correlated with endometrial carcinoma pathogenesis. Arch Gynecol Obstet. 2021;303(1):207–215. doi:10.1007/s00404-020-05791-0
   PubMed Web of Science ®Google Scholar
• Zhang C, Shao S, Zhang Y, et al. LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2. Life Sci. 2020;243:117295. doi:10.1016/j.lfs.2020.117295
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang C, Wei X, et al. CARLo-5 as an oncogenic gene in endometrial carcinoma. Environ Mol Mutagen. 2020;61(2):256–265. doi:10.1002/em.22340
   PubMed Web of Science ®Google Scholar
• Zhu W, Ye Z, Chen L, Liang H, Cai Q. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma. Int Immunopharmacol. 2021;101(Pt B):108268. doi:10.1016/j.intimp.2021.108268
   PubMed Web of Science ®Google Scholar
• Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19(4):197–214. doi:10.1038/s41568-019-0123-y
   PubMed Web of Science ®Google Scholar
• Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6–21. doi:10.1111/imr.12296
   PubMed Web of Science ®Google Scholar
• Wang B, Yin Q. AIM2 inflammasome activation and regulation: a structural perspective. J Struct Biol. 2017;200(3):279–282. doi:10.1016/j.jsb.2017.08.001
   PubMed Web of Science ®Google Scholar
• Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-”host”? Cell Death Dis. 2019;10(9):650. doi:10.1038/s41419-019-1883-8
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Lai J, Chen B, Zhang G, Li X, Mok H, Liao N. Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature. J Transl Med. 2020;18(1):416. doi:10.1186/s12967-020-02578-4
   PubMed Web of Science ®Google Scholar
• Revythis A, Shah S, Kutka M, et al. Unraveling the wide spectrum of melanoma biomarkers. Diagnostics. 2021;11(8):1341. doi:10.3390/diagnostics11081341
   Web of Science ®Google Scholar
• Bao G, Xu R, Wang X, et al. Identification of lncRNA signature associated with pan-cancer prognosis. IEEE J Biomed Health Inform. 2021;25(6):2317–2328. doi:10.1109/jbhi.2020.3027680
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Hussen BM, Gharebaghi A, Eghtedarian R, Taheri M. LncRNA signature in colorectal cancer. Pathol Res Pract. 2021;222:153432. doi:10.1016/j.prp.2021.153432
   PubMed Web of Science ®Google Scholar
• Deng Y, Yuan W, Ren E, Wu Z, Zhang G, Xie Q. A four-methylated LncRNA signature predicts survival of osteosarcoma patients based on machine learning. Genomics. 2021;113(1 Pt 2):785–794. doi:10.1016/j.ygeno.2020.10.010
   PubMed Web of Science ®Google Scholar
• Gao H, Wu B, Jin H, Yang W. A 6-lncRNA signature predicts prognosis of diffuse large B-cell lymphoma. J Biochem Mol Toxicol. 2021;35(6):1–12. doi:10.1002/jbt.22768
   Web of Science ®Google Scholar
• Wang J, Shen C, Dong D, Zhong X, Wang Y, Yang X. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. Int Immunopharmacol. 2021;90:107146. doi:10.1016/j.intimp.2020.107146
   PubMed Web of Science ®Google Scholar
• Sun Y, Gao X, Li P, Song L, Shi L. LncRNA ZFAS1, as a poor prognostic indicator, promotes cell proliferation and epithelial-mesenchymal transition in endometrial carcinoma. Per Med. 2021;18(1):43–53. doi:10.2217/pme-2020-0014
   PubMed Web of Science ®Google Scholar
• Hessmann E, Buchholz SM, Demir IE, et al. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020;100(4):1707–1751. doi:10.1152/physrev.00042.2019
   PubMed Web of Science ®Google Scholar
• Menter T, Tzankov A, Dirnhofer S. The tumor microenvironment of lymphomas: insights into the potential role and modes of actions of checkpoint inhibitors. Hematol Oncol. 2021;39(1):3–10. doi:10.1002/hon.2821
   PubMed Web of Science ®Google Scholar
• Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018;31(6):659–669. doi:10.20524/aog.2018.0305
   PubMed Web of Science ®Google Scholar
• de Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–110. doi:10.1016/j.ygyno.2009.03.022
   PubMed Web of Science ®Google Scholar
• Čermáková P, Melichar B, Tomšová M, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res. 2014;34(10):5555–5561.
   PubMed Web of Science ®Google Scholar
• Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10(13):4450–4456. doi:10.1158/1078-0432.Ccr-0732-3
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/po.17.00073
   PubMed Web of Science ®Google Scholar
• Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–1323. doi:10.1001/jamaoncol.2015.2151
   PubMed Web of Science ®Google Scholar
• Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–7. doi:10.1200/edbk_280503
   PubMedGoogle Scholar